Gonca HANEDAN USLU, Lasif SERDAR, Özlem AYNACI, Ahmet ZENGİN, Emine CANYILMAZ

Evaluation of Prognostic Factors and Survival Results in Geriatric Patients with Head and Neck Cancer

Length of life is gradually increasing along with the incidence of cancer in the elderly. Herein, we aimed to evaluate radiotherapy (RT) and chemoradiotherapy (CRT), surgical treatment (ST) results, clinico pathological features, and survival factors in patients ≥65-years-old with head-and-neck cancer. METHODS We evaluated patients aged ≥65 years with head-and-neck cancer who were treated in radiation oncol ogy clinics in the Eastern Black Sea region of Turkey. After receiving the approval of the Ethics Commit tee, demographic, clinical, and histopathological data of the patients were obtained by reviewing their files and records. RESULTS Of 179 patients with head-and-neck cancer, 59 (33%) were geriatric patients. Thirty-three patients were treated only with RT, 24 with CRT, and two with ST. The total RT dose ranged from 66 to 70 Gy, and 40 mg/m2 cisplatin could be weekly administered. While 50.8% of the patients had laryngeal cancer, 22% had oral cavity cancer. The mean follow-up period was 29.3 months; median overall survival (OS) was 27.5 months; 2- and 5-year OS were 56.6% and 32.2%, respectively; median progression-free survival was 25.4 months. When prognostic factors that could affect general survival were analyzed in a univari ate analysis, sex status (p=0.019) was found statistically significant. The most common side effect was Grade 3 mucositis (30%). CONCLUSION Treatment modalities to be selected in elderly patients with head-and-neck cancer should be evaluated based on the performance status and not age. Elderly patients with no additional comorbidity can be treated with RT and/or CRT in a similar to that done in young patients.

PDF

___

1. Ramesh HS, Pope D, Gennari R, Audisio RA. Opti mizing surgical management of elderly cancer pa tients. World J Surg Oncol 2005;3(1):17.
2. Balducci L, Lyman GH, Ershler WB, Extermann M. Comprehensive Geriatric Oncology. 2nd ed. Boca Ra ton, FL: Taylor & Francis Group; 2004. p. 1267–79.
3. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009;27(17):2758–65.
4. de Rijke JM, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, van den Brandt PA. Age-specific differ ences in the diagnosis and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol 1996;7(7):677–85.
5. Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, et al. Cancer in the elderly: Why so badly treated? Lancet 1990;335(8696):1020–2.
6. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US food and drug adminis tration. J Clin Oncol 2004;22(22):4626–31.
7. Gunn WG. Radiation therapy for the aging patient. CA Cancer J Clin 1980;30(6):337–47.
8. Olmi P, Ausili-Cefaro G. Radiotherapy in the elderly: A multicentric prospective study on 2060 patients referred to 37 Italian radiation therapy centers. Rays 1997;22 Suppl 1:53–6.
9. Metges JP, Eschwege F, de Crevoisier R, Lusinchi A, Bourhis J, Wibault P. Radiotherapy in head and neck cancer in the elderly: A challenge. Crit Rev Oncol He matol 2000;34(3):195–203.
10.Hirano M, Mori K. Management of cancer in the el derly: Therapeutic dilemmas. Otolaryngol Head Neck Surg 1998;118(1):110–4.
11.Kennedy BJ. Aging and cancer. J Clin Oncol 1988;6(12):1903–11.
12.Gourin CG, McAfee WJ, Neyman KM, Howington JW, Podolsky RH, Terris DJ. Effect of comorbidity on the quality of life and treatment in patients with squa mous cell carcinoma of the head and neck. Laryngo scope 2005;115(8):1371–5.
13.Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 2007;14(4):1449–57.
14.Yancik R, Ries LA. Cancer in older persons. Magni tude of the problem-how do we apply what we know? Cancer 1994;74 Suppl 7:1995–2003.
15.Güney E, Çağlı S, Yüce İ. Head and neck cancers in geriatric patients. Kulak Burun Bogaz Ihtis Derg 2009;19(1):45–54.
16.Clayman GL, Eicher SA, Sicard MW, Razmpa E, Goepfert H. Surgical outcomes in head and neck cancer patients 80 years of age and older. Head Neck 1998;20(3):216–23.
17.Baumann M. Is curative radiation therapy in elderly patients limited by increased normal tissue toxicity? Radiother Oncol 1998;46(3):225–7.
18.Ampil FL, Mills GM, Stucker FJ, Burton GV, Nathan CO. Radical combined treatment of locally extensive head and neck cancer in the elderly. Am J Otolaryngol 2001;22(1):65–9.
19.Zachariah B, Balducci L, Venkattaramanabalaji GV, Casey L, Greenberg HM, DelRegato JA. Radiotherapy for cancer patients aged 80 and older: A study of effec tiveness and side effects. Int J Radiat Oncol Biol Phys 1997;39(5):1125–9.
20.Allal AS, Maire D, Becker M, Dulguerov P. Feasibil ity and early results of radiotherapy for head and neck carcinoma in the elderly. Cancer 2000;88(3):648–52.